Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 158.66% | 113.26% | 82.50% | 78.00% | 64.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.66% | 113.26% | 82.50% | 78.00% | 64.00% |
| Cost of Revenue | -67.66% | -78.18% | -82.71% | -59.41% | -22.53% |
| Gross Profit | 360.19% | 390.65% | 426.26% | 545.00% | -- |
| SG&A Expenses | -26.90% | -40.72% | -48.81% | -46.23% | -43.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -21.35% | 47.54% | 63.02% | 85.31% | 92.44% |
| Total Operating Expenses | -15.43% | -28.48% | -37.20% | -42.30% | -45.47% |
| Operating Income | 17.04% | 29.91% | 38.48% | 43.04% | 45.80% |
| Income Before Tax | 16.87% | 25.65% | 31.56% | 63.68% | 72.94% |
| Income Tax Expenses | -- | -- | -- | -2,981.82% | -203.49% |
| Earnings from Continuing Operations | 16.19% | 25.07% | 31.05% | 63.84% | 73.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.19% | 25.07% | 31.05% | 63.84% | 73.22% |
| EBIT | 17.04% | 29.91% | 38.48% | 43.04% | 45.80% |
| EBITDA | 17.56% | 30.26% | 38.83% | 43.67% | 46.39% |
| EPS Basic | 33.24% | 49.16% | 58.01% | 76.96% | 81.69% |
| Normalized Basic EPS | 33.81% | 53.52% | 63.55% | 63.32% | 63.00% |
| EPS Diluted | 33.24% | 49.16% | 58.01% | 76.96% | 81.69% |
| Normalized Diluted EPS | 33.81% | 53.52% | 63.55% | 63.32% | 63.00% |
| Average Basic Shares Outstanding | 16.20% | 38.51% | 64.01% | 61.60% | 58.84% |
| Average Diluted Shares Outstanding | 16.20% | 38.51% | 64.01% | 61.60% | 58.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |